Skip to main content
SpringerLink
Log in

The Role of the Oncologist in the Treatment of Colorectal Cancer

  • Chapter
Progress in Colorectal Surgery

  • 524 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systemic review and meta-analysis. BMJ. 2000;321:531–535.

    Google Scholar 

  2. The Advanced Colorectal Cancer Meta-analysis Project. Meta-analysis of randomised trials testing the biochemical modulation of 5-fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol. 1994; 12:960–969.

    Google Scholar 

  3. The Advanced Colorectal Cancer Meta-analysis Project. Modulation of 5FU byleucovorin in patients with advanced colorectal cancer; evidence in terms of response rate. J Clin Oncol. 1992;10:896–903.

    Google Scholar 

  4. Petrelli N, Douglas HO, Herrera L, et al. The modulation of 5FU with leucovorin in metastatic colorectal carcinoma: a prospective randomised phase III trial. J Clin Oncol. 1989;7:1419–1426.

    PubMed  CAS  Google Scholar 

  5. Poon MA, O’Connell MJ, Wieand S, et al. Biochemical modulation of 5FU with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol. 1991;9: 1967–1972.

    PubMed  CAS  Google Scholar 

  6. Myers CE, Diaslo R, Eliot HM, et al. Pharmocokinetics of the fluoropyrimides: implications for their clinical use. Cancer Treat Rev. 1975;3:175–183.

    Google Scholar 

  7. Fraile RJ, Baker LH, Baroker TR, et al. Pharmocokinetics of 5FU administered orally, by rapid intravenous and by slow infusion. Cancer Res. 1980;40:2223–2228.

    PubMed  CAS  Google Scholar 

  8. Aschele C, Sobiero A, Faderan MA, et al. Novel mechanisms of resistance to 5FU in human colon cancer (HCT 8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 1992;52: 1855–1864.

    PubMed  CAS  Google Scholar 

  9. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of 5FU compared with bolus administration in advanced colorectal cancer. . J Clin Oncol. 1998;16:301–308.

    Google Scholar 

  10. Pazdur R, Douillard JY, Skillings JR, et al. Multicentre phase III study of 5FU or UFT in combination with leucovorin in patients with metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol. 1999;18: 1009.

    Google Scholar 

  11. Twelves C, Harper P, Van Cutsem E. A phase III trial (S014796) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol. 1999;18:1010.

    Google Scholar 

  12. Carmichael J, Popiela T, Radstone D, et al. Randomised comparative study of ORZEL (oral uracil/tegafur) plus leucovorin (IV) versus parenteral 5FU plus leucovorin in patients with metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol. 1999;18:1015.

    Google Scholar 

  13. Cox JV, Pazdur R, Thibault A, et al. A phase II trial of Xeloda TM (capecitabine) in previously untreated advanced/metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol. 1999;18:1016.

    Google Scholar 

  14. Meta-analysis Group in Cancer. Re-appraisal of hepatic arterial infusion in the treatment of non-resectable liver metastases from colorectal cancer. J Natl Cancer Inst. 1996;88:252–258.

    Google Scholar 

  15. Bleiberg H. CPT-11 in gastro-intestinal cancer. Eur J Cancer. 1999;35:371–379.

    Article  PubMed  CAS  Google Scholar 

  16. Pitot HC, Wender DB, O’Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 1997;15:2910–2919.

    PubMed  CAS  Google Scholar 

  17. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy naïve patients and patients pre-treated with 5FU-based chemptherapy. J Clin Oncol. 1997;15:251–260.

    PubMed  CAS  Google Scholar 

  18. Rothenberg ML, Eckard JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996;14:1128–1135.

    PubMed  CAS  Google Scholar 

  19. Van Cutsem E, Rougier P, Droz JP, et al. Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer resistant to 5FU [abstract]. Proc ASCO. 1997;16:268a.

    Google Scholar 

  20. Rougier P, Van Cutsem E, Bajetta E. Randomised trial of irinotecan versus 5FU by continuous infusion after 5FU failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407–1412.

    Article  PubMed  CAS  Google Scholar 

  21. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after 5FU failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413–1418.

    Article  PubMed  CAS  Google Scholar 

  22. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with 5FU compared with 5FU alone as first line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355: 1041–1047.

    Article  PubMed  CAS  Google Scholar 

  23. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus 5FU plus leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905–914.

    Article  PubMed  CAS  Google Scholar 

  24. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin, a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053–1071.

    Article  PubMed  CAS  Google Scholar 

  25. DeGramont A, Vignoud J, Tournigant C, et al. Oxaliplatin with high dose leucovorin and 5FU 48 hour continuous infusion in pre-treated metastatic colorectal cancer. Eur J Cancer. 1997;32:214–219.

    Google Scholar 

  26. DeGramont A, Figer A, Seymour M, et al. Leucovorin plus 5FU with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947.

    CAS  Google Scholar 

  27. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multi-centre randomised trial of oxaliplatin added to chronomodulated 5FU-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol. 2000; 18:136–147.

    PubMed  CAS  Google Scholar 

  28. Abulfi AM, Williams NS. Local recurrence of colorectal cancer: the problems, the mechanisms, management and adjuvant treatment. Br J Surg. 1994;81:7–17.

    Google Scholar 

  29. De Wys WD. Studies correlating the growth rate of a tumour and its metastases and providing evidence for tumour related systemic growth retarding factors. Cancer Res. 1972;32:374–379.

    Google Scholar 

  30. Moertal CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for the adjuvant treatment of resected colon cancer. N Engl J Med. 1990;322:352–358.

    Google Scholar 

  31. IMPACT trial. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345:939–944.

    Google Scholar 

  32. O’Connell M, Maillard J, Kahn MJ, et al. Controlled trial of fluorouracil and low dose leucovorin given for six months as post-operative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15:246–250.

    PubMed  CAS  Google Scholar 

  33. Wolmark N, Rockette H, Fisher, B et al. The benefit of leucovorin modulated 5 fluorouracil as post-operative adjuvant treatment for primary colon cancer:results from the National Surgery and Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol. 1993;11:1879–1888.

    PubMed  CAS  Google Scholar 

  34. O’Connell MJ, Lauie JA, Shepherd L, et al. A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high risk colon cancer: a collaborative trial of North Central Cancer Treatment group and the National Cancer Institute of Canada Clinical trials Group [abstract]. Proc Am Soc Clin Oncol. 1996; 15:209.

    Google Scholar 

  35. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000;355: 1588–1596.

    Google Scholar 

  36. Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer, a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst. 1997;89:497–505.

    Google Scholar 

  37. Bosset JF, Mantion G, Lorchel F, et al. Adjuvant and neoadjuvant radiation therapy for rectal cancer. Semin Oncol. 2000;27:60–65.

    PubMed  CAS  Google Scholar 

  38. Pahlman L. Pre-operative treatment of rectal cancer. In: Management of Colorectal Cancer. Bleiberg H, Rougier P, Wilke HJ, eds. London: Martin Dunitz, 1998:153–166.

    Google Scholar 

  39. Swedish Rectal Cancer Trial. Local recurrence rate in a randomised multicentre trial of pre-operative radiotherapy compared to surgery alone in resectable rectal cancer. Eur J Surg. 1996;162:397–402.

    Google Scholar 

  40. James RD, Haboubi N, Schofield PF, et al. Prognostic factors in colorectal cancer treated by pro-operative radiotherapy and immediate surgery. Dis Colon Rectum. 1991;34:546–551.

    Article  PubMed  CAS  Google Scholar 

  41. Gerard A, Buyse M, Nordlinger B, et al. Pre-operative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomised study of the EORTC Gastrointestinal Tract Cancer Co-operative Group. Ann Surg. 1988;208:606–614.

    Article  PubMed  CAS  Google Scholar 

  42. Stockholm Rectal Cancer Study Group. Preoperative short term radiation therapy in operable rectal carcinoma. Cancer 1990;66:49–53.

    Article  Google Scholar 

  43. Balsler I, Pederson M, Teglbjaerg PS, et al. Postoperative radiotherapy in Dukes B and C carcinoma of the rectum and rectosigmoid: a randomised multicentre study. Cancer 1986;58:22–28.

    Google Scholar 

  44. Gastrointestinal Tumour Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med. 1985;312:1464–1472.

    Google Scholar 

  45. Fisher B, Wolmark N, Rockette H, et al. Post-operative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP Protocol R-01. J Natl Cancer Inst. 1988;80:21–29.

    PubMed  CAS  Google Scholar 

  46. MRC Rectal Cancer Working Party. Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Lancet 1996;348:1610–1614.

    Google Scholar 

  47. Jansson-Frykholm G, Glimelius B, Pahlman L. Pre-operative or post-operative radiotherapy in adenocarcinoma of the rectum: final treatment results of a randomised trial and an evaluation of late secondary effects. Dis Colon Rectum. 1993;36:564–572.

    Google Scholar 

  48. O’Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted infusion 5FU with radiation therapy after curative surgery. N Engl J Med. 1994;331: 502–507.

    PubMed  CAS  Google Scholar 

  49. Reithmuller G, Schneider-Gadicke E, Schmilok G. Randomised trial of monoclonal antibody for adjuvant treatment of resected Dukes C colorectal. Lancet 1994;343:1177–1183.

    Google Scholar 

  50. Kerr DJ, Midgley RS. Immunotherapy for colorectal cancer: potential application in an adjuvant setting. Semin Oncol. 2000;27(suppl 10):132–137.

    PubMed  CAS  Google Scholar 

  51. Venook AP, Bergsland EK, Ring E, et al. Gene therapy of colorectal liver metastases using a recombinant adenovirus encoding WT p53 (sat 58500) via hepatic artery infusion: a phase I study. Proc ASCO. 1998; 17: 431a.

    Google Scholar 

  52. Huber BE, Austin EA, Good SS, et al. In vivo anti-tumour activity of 5FU on human colorectal cancer cells genetically modified to express cytosine deaminase. Cancer Res. 1993;53:4619–4626.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CRC Institute for Cancer Studies, University of Birmingham, Birmingham, UK

    Shibani Nicum BSc, MRCP

  2. CRC Institute for Cancer Studies, University of Birmingham, Birmingham, UK

    Rachel Midgley BSc, MRCP

  3. National Translational Cancer Research Network, Department of Clinical Pharmacology, University of Oxford, Oxford, UK

    David J. Kerr CBE, MA, MD, DSc, FRCP, FMedSci

Authors
  1. Shibani Nicum BSc, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel Midgley BSc, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David J. Kerr CBE, MA, MD, DSc, FRCP, FMedSci
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Colorectal Surgery, Singleton Hospital, Swansea, UK

    John Beynon BSc, MS, FRCS  & Nicholas D. Carr MD, FRCS  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag London Limited

About this chapter

Cite this chapter

Nicum, S., Midgley, R., Kerr, D.J. (2005). The Role of the Oncologist in the Treatment of Colorectal Cancer. In: Beynon, J., Carr, N.D. (eds) Progress in Colorectal Surgery. Springer, London. https://doi.org/10.1007/1-84628-058-3_10

Download citation

  • DOI: https://doi.org/10.1007/1-84628-058-3_10

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-823-7

  • Online ISBN: 978-1-84628-058-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation